Literature DB >> 2185878

Differential expression of ros oncogene in primary human astrocytomas and astrocytoma cell lines.

J K Wu1, D M Chikaraishi.   

Abstract

Overexpression of oncogenes has been associated with the pathogenesis of some human cancers. The ros oncogene, which encodes a putative receptor with tyrosine kinase activity, has been recently shown to be specifically expressed in high levels in human astrocytoma and glioblastoma cell lines. Using transcription mapping analysis, we surveyed 25 primary astrocytomas of all histological grades, including glioblastomas, and failed to demonstrate elevated expression of ros in these tumors. This difference between the cell lines and the primary tumors may be due to dilution of the ros-positive clones by larger populations of ros-negative cells in the primary tumors or to induction of ros oncogene when the tumors are adapted to tissue culture.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185878

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 2.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 3.  The autocrine loop of TGF-alpha/EGFR and brain tumors.

Authors:  P Tang; P A Steck; W K Yung
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 4.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

5.  Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction.

Authors:  K Aka; J M Bruner; M L Bondy; K Ligon; T Nishi; A del Giglio; R P Moser; V A Levin; H Saya
Journal:  J Neurooncol       Date:  1993-05       Impact factor: 4.130

6.  Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.

Authors:  Monika A Davare; Jacob J Henderson; Anupriya Agarwal; Jacob P Wagner; Sudarshan R Iyer; Nameeta Shah; Randy Woltjer; Romel Somwar; Stephen W Gilheeney; Ana DeCarvalo; Tom Mikkelson; Erwin G Van Meir; Marc Ladanyi; Brian J Druker
Journal:  Clin Cancer Res       Date:  2018-08-31       Impact factor: 12.531

7.  Tumor grade related expression of neuroglobin is negatively regulated by PPARγ and confers antioxidant activity in glioma progression.

Authors:  Jing Hu; Xiyue Cao; Dejiang Pang; Qihui Luo; Yuanfeng Zou; Bin Feng; Lixia Li; Zhengli Chen; Chao Huang
Journal:  Redox Biol       Date:  2017-04-01       Impact factor: 11.799

Review 8.  Genetically engineered mouse models of brain cancer and the promise of preclinical testing.

Authors:  Jason T Huse; Eric C Holland
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

9.  Overexpression of multiple oncogenes related to histological grade of astrocytic glioma.

Authors:  J M Orian; K Vasilopoulos; S Yoshida; A H Kaye; C W Chow; M F Gonzales
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.